Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345142 | 0.90 | GRIN1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL23997444 | 0.90 | GRIN1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL25719543 | 0.71 | ALDH1A1 (0.50) | NPC1ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL24405792 | 0.71 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL25718704 | 0.71 | MIF (0.62) | ALDH1A1TSHRPARGKMT2AMEN1 | |
| SCHEMBL25719533 | 0.71 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL23997180 | 0.70 | PARG (0.59) | PARGKMT2APOLBLMNA | |
| SCHEMBL30336927 | 0.70 | PARG (0.59) | PARGKMT2APOLBLMNA | |
| Trifluoroacetic Acid SCHEMBL31197678 | 0.69 | MEN1 (0.58) | NPC1SMN1; SMN2ALDH1A1TSHRPARG | |
| SCHEMBL25719546 | 0.69 | ALDH1A1 (0.46) | NPC1SMN1; SMN2ALDH1A1TSHRPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | NPC1 657/4885RAB9A 3126/4885SMN1; SMN2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.